ICON Yönetim
Yönetim kriter kontrolleri 4/4
ICON CEO'su Steve Cutler, Mar2017 tarihinde atandı, in görev süresi 7.67 yıldır. in toplam yıllık tazminatı $ 7.24M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.4% maaş ve 83.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.045% ine doğrudan sahiptir ve bu hisseler $ 8.12M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.3 yıl ve 7.6 yıldır.
Anahtar bilgiler
Steve Cutler
İcra Kurulu Başkanı
US$7.2m
Toplam tazminat
| CEO maaş yüzdesi | 16.4% |
| CEO görev süresi | 7.7yrs |
| CEO sahipliği | 0.04% |
| Yönetim ortalama görev süresi | 8.3yrs |
| Yönetim Kurulu ortalama görev süresi | 7.6yrs |
Son yönetim güncellemeleri
Recent updates
With A 25% Price Drop For ICON Public Limited Company (NASDAQ:ICLR) You'll Still Get What You Pay For
Nov 02
Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors
Sep 25Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Sep 09We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Aug 25An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued
Aug 10ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)
Jul 13Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)
Jun 14Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching
May 30ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 14ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Dec 09With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Nov 08Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Oct 09Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Sep 23Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Sep 05Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 03Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jun 30Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Jun 12Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
May 23Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Mar 29Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Mar 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?
Feb 21Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Dec 28These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Dec 10Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?
Nov 22Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?
Sep 15ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly
Aug 26Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
Aug 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?
Aug 01CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$748m |
| Jun 30 2024 | n/a | n/a | US$714m |
| Mar 31 2024 | n/a | n/a | US$683m |
| Dec 31 2023 | US$7m | US$1m | US$612m |
| Sep 30 2023 | n/a | n/a | US$513m |
| Jun 30 2023 | n/a | n/a | US$510m |
| Mar 31 2023 | n/a | n/a | US$510m |
| Dec 31 2022 | US$10m | US$1m | US$505m |
| Sep 30 2022 | n/a | n/a | US$464m |
| Jun 30 2022 | n/a | n/a | US$210m |
| Mar 31 2022 | n/a | n/a | US$168m |
| Dec 31 2021 | US$10m | US$1m | US$153m |
| Sep 30 2021 | n/a | n/a | US$178m |
| Jun 30 2021 | n/a | n/a | US$364m |
| Mar 31 2021 | n/a | n/a | US$338m |
| Dec 31 2020 | US$8m | US$1m | US$328m |
| Sep 30 2020 | n/a | n/a | US$322m |
| Jun 30 2020 | n/a | n/a | US$324m |
| Mar 31 2020 | n/a | n/a | US$368m |
| Dec 31 2019 | US$8m | US$1m | US$369m |
| Sep 30 2019 | n/a | n/a | US$362m |
| Jun 30 2019 | n/a | n/a | US$353m |
| Mar 31 2019 | n/a | n/a | US$333m |
| Dec 31 2018 | US$8m | US$1m | US$323m |
| Sep 30 2018 | n/a | n/a | US$306m |
| Jun 30 2018 | n/a | n/a | US$295m |
| Mar 31 2018 | n/a | n/a | US$288m |
| Dec 31 2017 | US$7m | US$1m | US$281m |
Tazminat ve Piyasa: Steve 'nin toplam tazminatı ($USD 7.24M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 12.88M ).
Tazminat ve Kazançlar: Steve 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Steve Cutler (64 yo)
7.7yrs
Görev süresi
US$7,244,000
Tazminat
Dr. Steven A. Cutler, also known as Steve, Ph D., MBA, serves as Chairman of Association of Clinical Research Organizations since January 01, 2021. He has been the Chief Executive Officer of ICON Public Li...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 7.7yrs | US$7.24m | 0.045% $ 8.1m | |
| Founder & Independent Non-Executive Director | no data | US$290.00k | 0.54% $ 98.4m | |
| Chief Financial Officer | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Corporate & Commercial Finance | no data | Veri yok | Veri yok | |
| Chief Information Officer | no data | Veri yok | Veri yok | |
| Chief Administrative Officer | 15yrs | Veri yok | 0.0097% $ 1.7m | |
| Director of Corporate Communications | no data | Veri yok | Veri yok | |
| Vice President of Marketing | no data | Veri yok | Veri yok | |
| Chief Human Resources Officer | 8.3yrs | Veri yok | Veri yok | |
| President of Corporate Investments & Partnerships | 2yrs | Veri yok | Veri yok | |
| Senior Vice President of Global Clinical Pharmacology | 15.6yrs | Veri yok | Veri yok | |
| Senior Vice President of Drug Development Services - CNS | 17.8yrs | Veri yok | Veri yok |
8.3yrs
Ortalama Görev Süresi
53.5yo
Ortalama Yaş
Deneyimli Yönetim: ICLR 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 9yrs | US$7.24m | 0.045% $ 8.1m | |
| Founder & Independent Non-Executive Director | 14.8yrs | US$290.00k | 0.54% $ 98.4m | |
| Independent Director | 3.3yrs | US$303.00k | 0.0054% $ 970.0k | |
| Independent Non-Executive Director | 7.1yrs | US$323.00k | 0.0026% $ 464.2k | |
| Independent Non-Executive Chairman of the Board | 13.1yrs | US$656.00k | 0.023% $ 4.2m | |
| Lead Independent Director | 8.1yrs | US$359.00k | 0.0026% $ 464.2k | |
| Non-Executive Director | less than a year | Veri yok | Veri yok | |
| Independent Non-Executive Director | 5.3yrs | US$315.00k | 0.0023% $ 422.7k |
7.6yrs
Ortalama Görev Süresi
64.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ICLR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.6 yıldır).